Signos raises $20.0M (United States, May 2026)
$20.0M
$20MGenerated social card
Headline
Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss - MedCity News
About
Signos is a health technology company that focuses on using continuous glucose monitoring (CGM) technology to help individuals manage their weight. The company aims to expand the application of CGM beyond diabetes, targeting consumers interested in weight loss solutions. This funding round will support their efforts to broaden the use of CGM technology in the weight management market.
Article summary
Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss MedCity News
Investors
Related rounds
| Jun 19, 2026 | DeductiveAI | $7.5M | Series A | United States |
| Jun 18, 2026 | Baseten | $1.50B | Series F | United States |
| Jun 18, 2026 | Interchecks | $50.0M | Series C | United States |
| Jun 18, 2026 | American Perpetuals Exchange Corporation | $30.0M | — | United States |